Studies "open a new frontier in biotechnology and medicine," says Life Biosciences CEO.
Intellectual property generated by the scientific findings behind two recent publications in...
Company seeks $2 million to prepare IND application for repurposed drug for AMD ahead of Phase 2 trials.
Philadelphia-based start-up Drusolv Therapeutics is tackling age-related...
CohBar CEO on the development of a “true portfolio” of mitochondria based therapeutics.
US biotech company CohBar is developing mitochondria-based therapeutics for the treatment of...
Florida-based Longeveron files for a $30 million IPO, targeting aging-related conditions.
Longeveron, a Phase 2 biotech which develops cellular therapies for aging-related conditions, filed the...
Compound that extends lifespan in worms also slows bone loss in mice.
Scientists at the Buck Institute for Research on Aging conducted a longitudinal and functional study...
Longevity Labs+ seeks to validate efficacy of spermidine supplement through clinical studies; aspires to become the Red Bull of longevity supplements.
The home of famous...
Professor Andrew Scott outlines how society needs to change in order to capitalise on multi-trillion dollar longevity dividend.
Last week, we brought you the views...
UCL aims to help drive the fight against dementia by enlisting London's Black Cab drivers in a unique brain testing trial.
London’s black cab drivers, famed...
Deep Longevity releases an AI-based predictor of COVID time-to-death.
Deep Longevity, which is spearheading the provision of deep biomarkers of aging, has announced the publication...
